Araujo-Castro, M, Biagetti, B, Menéndez, E, Novoa-Testa, I, Cordido, F, Berrocal, VR, Pascual-Corrales, E, Guerrero-Pérez, F, Vicente, A, García-Centeno, R, Gonzalez, L, Garcia, MDO, Echarri, AI, Rodríguez, MDM, Novo-Rodríguez, C, Calatayud, M, Villar-Taibo, R, Bernabéu, I, Alvarez-Escola, C, Jimenez, CT, Abellan-Galiana, P, Venegas, E, González-Molero, I, Iglesias, P, Blanco, C, De Lara, FVO, Novoa, MPD, Torres, ELM, Hanzu, F, Lamas, C, Rodriguez, SA, Aulinas, A, Recio, JM, Aviles-Pérez, MD, Núñez, MAS, Camara, R, Fano, MP, Fajardo, C, Cardoso, L, Marques, P, Martínez-Sàez, E, Ruz-Caracuel, I, Marazuela, M, Puig-Domingo, M. Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas. Endocrine Connections. 2025; 14(7)DOI:10.1530/EC-25-0103. PMID:40590355. IF:2.800(Q3/6D).

Villamarín , M, Fernández-Hidalgo, N, Escolà-Vergé, L. Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre-a counterpoint. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2025; 80(7)DOI:10.1093/jac/dkaf164. PMID:40396694. IF:3.600(Q2/3D).

Mosnaim, GS, Price, D, Côté, A, Plaza, V, Xia, CM, Awad, H, Kwah, J. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AND ASTHMA CONTROL IN PATIENTS WITH AND WITHOUT COEXISTING TYPE 2 CONDITIONS: RESULTS FROM THE RAPID STUDY. VALUE IN HEALTH. 2025; 28(6)DOI:. PMID:. IF:6.000(Q1/1D).

Ryan, P, Blanco, JL, Masia, M, Garcia-Fraile, L, Crusells, MJ, Domingo, P, Curran, A, Guerri-Fernandez, R, Bernal, E, Bravo, J, Revollo, B, Macias, J, Tiraboschi, JM, Montejano, R, Amador, C, Torralba, M, Merino, D, Diaz-Brito, V, Galindo, MJ, Ferra, S, Villoslada, A, Losa, JE, Fanjul, FJ, Perez-Stachowski, X, Peraire, J, Portilla, J, de la Fuente, S, Dueñas, C, Vazquez, MJ, Di Gregorio, S, Esteban, H, Gil, P, de Miguel, M, Alejos, B, Martínez, E. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV. 2025; 12(7)DOI:10.1016/S2352-3018(25)00105-5. PMID:40489982. IF:13.000(Q1/1D).

Uyar, GC, Mirallas, O, Baskurt, K, Martin-Cullell, B, Yesilbas, E, Recuero-Borau, J, Kaya, S, Garcés, VN, Yücel, SE, Cano, KSV, Gómez-Puerto, D, Gómez, AP, de Torres, CS, Öksüzoglu, ÖBÇ, Serradell, S, Dienstmann, R, Sutcuoglu, O. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Lancet Regional Health-Europe. 2025; 54DOI:10.1016/j.lanepe.2025.101317. PMID:40672056. IF:13.000(Q1/1D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC (vol 6, 100815, 2025). Jto Clinical And Research Reports. 2025; 6(7)DOI:10.1016/j.jtocrr.2025.100842. PMID:40534993. IF:(Q/D).

Pietrantonio, F, Salvatore, L, Esaki, T, Modest, DP, Lopez-Bravo, DP, Taieb, J, Karamouzis, MV, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Chan, EMY, Chao, JS, Tran, Q, Cremolini, C, Fakih, M. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(19)DOI:10.1200/JCO-24-02026. PMID:40215429. IF:41.900(Q1/1D).

Bergmann, L, Albiges, L, Ahrens, M, Gross-Goupil, M, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthélémy, P, Castellano, D, Mellado, B, Ivanyi, P, Rottey, S, Flörcken, A, Suarez, C, Maroto, P, Grünwald, V, Oosting, SF, Kopecky, J, Zschäbitz, S, Boegemann, M, Buchler, T, Niegisch, G, Goebell, PJ, Waddell, T, Joly, F, Priou, F, Retz, M, Siemer, S, Zimmermann, U, Deckbar, D, Burkholder, I, Hartmann, A, Haanen, JB. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. ANNALS OF ONCOLOGY. 2025; 36(7)DOI:10.1016/j.annonc.2025.03.016. PMID:40180121. IF:65.400(Q1/1D).